Up­dat­ed: Bridge­Bio's AT­TR-CM drug bests place­bo in de­tailed PhI­II da­ta, bol­ster­ing plans for NDA

Bridge­Bio pre­sent­ed de­tailed pos­i­tive da­ta from its Phase III tri­al of aco­ramidis in pa­tients with transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) at the Eu­ro­pean So­ci­ety of Car­di­ol­o­gy Con­gress this week­end, bol­ster­ing its plans to seek FDA ap­proval this year.

Ex­ec­u­tives added on an in­vestor call this morn­ing that Bridge­Bio is al­so open to part­ner­ships to move the drug for­ward.

Pre­vi­ous­ly re­leased topline da­ta showed 81% of pa­tients get­ting the drug were alive at 30 months, com­pared with 74% on place­bo. Aco­ramidis al­so cut the rate of hos­pi­tal­iza­tion by 50%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER